Amplification of DDR2 mediates sorafenib resistance through NF‐κB/c‐Rel signaling in hepatocellular carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amplification of DDR2 mediates sorafenib resistance through NF‐κB/c‐Rel signaling in hepatocellular carcinoma
Authors
Keywords
-
Journal
CELL BIOLOGY INTERNATIONAL
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-05-10
DOI
10.1002/cbin.11625
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer
- (2020) Eva Galle et al. Clinical Epigenetics
- The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
- (2020) Shunjie Xia et al. EBioMedicine
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A structural prospective for collagen receptors such as DDR and their binding of the collagen fibril
- (2019) Joseph P.R.O. Orgel et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- A global view of hepatocellular carcinoma: trends, risk, prevention and management
- (2019) Ju Dong Yang et al. Nature Reviews Gastroenterology & Hepatology
- Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
- (2019) Ziyu Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma
- (2019) Ling Wei et al. Molecular Cancer
- Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
- (2018) Merly Contratto et al. World Journal of Gastrointestinal Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- DDR2 controls the epithelial-mesenchymal-transition-related gene expression via c-Myb acetylation upon matrix stiffening
- (2017) Daehwan Kim et al. Scientific Reports
- Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis
- (2017) An Tang et al. Abdominal Radiology
- c-Rel and its many roles in cancer: an old story with new twists
- (2016) Jill E Hunter et al. BRITISH JOURNAL OF CANCER
- Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma
- (2016) Aparna Jayachandran et al. Journal of Hematology & Oncology
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- DDR2 facilitates hepatocellular carcinoma invasion and metastasis via activating ERK signaling and stabilizing SNAIL1
- (2015) Binhui Xie et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway
- (2015) Changjun He et al. Oncotarget
- Prognosis of untreated hepatocellular carcinoma
- (2014) Edoardo G. Giannini et al. HEPATOLOGY
- BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
- (2014) Wei-Chien Huang et al. PLoS One
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
- (2012) Hashem B. El-Serag GASTROENTEROLOGY
- Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies
- (2012) Kian-Huat Lim et al. IMMUNOLOGICAL REVIEWS
- Transmembrane Collagen Receptors
- (2011) Birgit Leitinger Annual Review of Cell and Developmental Biology
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- Systemic therapy of hepatocellular carcinoma: Are we making progress?
- (2008) Patricia Roxburgh et al. ADVANCES IN THERAPY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started